A 5.1-month improvement in median progression-free survival — from 6.4 months on pembrolizumab monotherapy to 11.5 months on the high-dose fianlimab–cemiplimab combination — sounds like a clinically meaningful gain. It wasn’t enough. The trial missed statistical significance at p=0.0627, leaving Regeneron without a primary endpoint win in first-line unresectable or metastatic melanoma despite enrolling 1,546 patients across four arms. That gap between biological signal and statistical threshold is the central frustration here, and it raises a pointed question about whether the trial was simply underpowered for the hazard ratio it ultimately produced (HR 0.845) or whether the comparator arm — pembrolizumab monotherapy — performed better than historical benchmarks suggested it would.
The low-dose arm settles the dose question definitively. A hazard ratio of 0.931 with a p-value of 0.4661 means the 400 mg fianlimab dose adds nothing detectable over pembrolizumab alone. The high-dose arm is the only scientifically relevant result, and even there the confidence interval just grazes 1.0 at its upper bound (0.709–1.008). That shape — a lower bound well below 1.0, an upper bound that barely crosses it — reflects a real biological effect that the trial design could not confirm with sufficient precision. Pembrolizumab’s median PFS of 6.4 months in this trial is notably lower than what was seen in KEYNOTE-006 (approximately 8.4 months), which complicates any attempt to contextualize the absolute magnitude of the fianlimab benefit.
Regeneron’s pivot is already in motion. A separate Phase 3 head-to-head trial pitting the high-dose fianlimab combination against Opdualag — Bristol-Myers Squibb’s approved LAG-3 plus PD-1 doublet — remains ongoing. That design is strategically smarter: Opdualag already owns the LAG-3 space in melanoma, and a direct superiority or non-inferiority read against it is more commercially actionable than beating pembrolizumab monotherapy would have been. The failure here does not extinguish fianlimab’s future in this indication, but it resets the evidentiary burden entirely onto that Opdualag comparison.
The single result to watch is the overall survival readout from this trial, expected to be presented at an upcoming medical meeting. If the OS curves separate meaningfully — even without a PFS win — it changes the regulatory calculus and strengthens the scientific rationale heading into the Opdualag trial’s data cut.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
